Post Operative Tissue Fibrosis.

TTX333

ProductTarget & MOAIndicationPreclinicalPh.1Ph.2aPh.2bPh.3Reg FilingReg ApprovalMilestones
Post-operative tissue fibrosis
TTX333Novel cellular metabolism targets hypoxic pathwaysPelvic Surgeries
Phase 3 2026
ProductTarget & MOAIndicationPreclinicalPh.1Ph.2aPh.2bPh.3Reg FilingReg ApprovalMilestones
Post-operative tissue fibrosis
TTX333Novel cellular metabolism targets hypoxic pathwaysPelvic Surgeries
Phase 3 2026

Surgeons and patients will tell you it is a serious quality-of-life issue that affects millions of post-surgical patients with no effective solution (1), costs the healthcare system billions of dollars annually, and cutting away or taking down existing scar tissue from previous surgery, prolongs and complicates procedures (i.e. 1 in 5 risk of inadvertent bowel injury requiring re-operations).

  • Surgical adhesions are often more dangerous than ones that spontaneously develop and can be life-threatening and cause significant patient morbidity
  • Cost estimates exceed $5B annually just in the US
  • Adhesion-related abdominal pain is one of the most common admissions to the ER in the US; up to 1/3 of these patients are known to use opioids to manage pain (2-5)

90%

of pelvic and abdominal surgeries result in fibrosis.

Patients, Surgeons and Hospitals

“I am on disability for my adhesions. I am in pain every second of every day…” — Patient.

“This a young otherwise healthy woman, no history or smoking and does not drink, and who has been dealing with severe constipation all her life. She has been working with our motility Clinic. She has been on aggressive bowel regimens including fiber, extensive bowel preparation, and pharmacologic agents to improve her bowel function. These have not really accomplished the goal and the patient is quite dependent upon enemas and pharmacologic agents to have bowel function. This case was substantially more difficult than usual because of lysing adhesions/ scar tissue for 70 minutes.” — Surgeon

“Since the issue is so significant, why have we not heard about it before? We focus on infection, but the rate of adhesions is actually higher than infections. Annualized savings and revenue growth projections likely to be highly impactful. Keep the price manageable and it will be left to the surgeon’s discretion.” — Directors of Clinical Pharmacy, Large Hospital Health System

Game changer for patients and surgeons:

TTX-333 is the first investigational drug to demonstrate, in a Level 1a double blind randomized controlled trial, clinically meaningful prevention of post-operative adhesions with a 93.3% efficacy rate. (6)

  • Attack the fibrosis biology of adhesion formation: TTX-333 distinguishes itself from physical anti-adhesion barriers by systemically modulating fibrotic pathways, thereby preventing adhesions throughout the entire peritoneal cavity rather than at a localized surgical site.
  • Flexibility of use: It can be easily used in laparoscopic procedures, which expands the market, given trends towards minimally invasive and robotic procedures
  • Ease of use: no training or capital equipment investment required by the hospital.
  • Safety: Phase 2 study showed no statistically significant in safety parameters between treatment and control.

Early Access, Compassionate Use, Right to Try

In certain cases, patients are eligible to access experimental drugs while still in clinical development. Every jurisdiction has its own regulations that may provide early access.

Email Us
Learn More
 

“Tissue fibrosis causes adhesions which are a big problem, and we would use this drug in every procedure.”

Dr. Rudy Leon De Wilde

“Post surgical adhesions are a big problem, and we would use this drug in every procedure.”
Dr. Rudy Leon De Wilde
Dr. Rudy Leon De Wilde
“TTX333 offers a potential therapeutic option for preventing adhesion formation based on sound scientific principles with the exciting triad of Efficacy, Safety and Ease of Use.”
Dr. James Greenberg
Dr. James GreenbergMD, FACOG, Boston, MA.
“This is the 4x4 for adhesion prevention. The trial design is Class 1 evidence and we look forward to this product being on the market.”
Dr. Antonio Garguilo,
Dr. Antonio Garguilo,MD, FACOG, Boston, MA

References

  1. Ahmad G, Kim K, Thompson M, Agarwal P, O’Flynn H, Hindocha A, et al. Barrier agents for adhesion prevention after gynaecological surgery. Cochrane Database Syst Rev. 2020;3:CD000475. Epub 2020/03/22. doi: 10.1002/14651858.CD000475.pub4. PubMed PMID: 32199406; PubMed Central PMCID: PMC7085418.
  2. De Wilde RL, Devassy R, Broek RPGT, Miller CE, Adlan A, Aquino P, et al. The Future of Adhesion Prophylaxis Trials in Abdominal Surgery: An Expert Global Consensus. J Clin Med. 2022;11(6). Epub 20220308. doi: 10.3390/jcm11061476. PubMed PMID: 35329802; PubMed Central PMCID: PMC8950418.
  3. Krielen P, Stommel MWJ, Pargmae P, Bouvy ND, Bakkum EA, Ellis H, et al. Adhesion-related readmissions after open and laparoscopic surgery: a retrospective cohort study (SCAR update). Lancet. 2020;395(10217):33-41. doi: 10.1016/S0140-6736(19)32636-4. PubMed PMID: 31908284.
  4. Ten Broek RP, Issa Y, van Santbrink EJ, Bouvy ND, Kruitwagen RF, Jeekel J, et al. Burden of adhesions in abdominal and pelvic surgery: systematic review and met-analysis. BMJ. 2013;347:f5588. Epub 2013/10/03. PubMed PMID: 24092941; PubMed Central PMCID: PMC3789584.
  5. Van den Beukel BAW, Stommel MWJ, van Leuven S, Strik C, IJsseldijk MA, Joosten F, et al. A Shared Decision Approach to Chronic Abdominal Pain Based on Cine-MRI: A Prospective Cohort Study. Am J Gastroenterol. 2018;113(8):1229-37. Epub 2018/06/27. doi: 10.1038/s41395-018-0158-9. PubMed PMID: 29946174.
  6. Chizen DR, Rislund DC, Robertson LM, Lim HJ, Tulandi T, Gargiulo AR, et al. A randomized double-blind controlled proof-of-concept study of alanyl-glutamine for reduction of post-myomectomy adhesions. Eur J Obstet Gynecol Reprod Biol. 2023;284:180-8. Epub 20230329. doi: 10.1016/j.ejogrb.2023.03.032. PubMed PMID: 37023559.

30%

of patients undergoing abdominal surgery will be readmitted due to an adhesion complication within 10 years.